Elranatamab Represents Another Off-the-Shelf Option for Heavily Pretreated R/R Myeloma
Ajay Kumar Nooka, MD, MPH, FACP, highlights the significance of the FDA approval of elranatamab for select patients with relapsed/refractory multiple myeloma and sheds light on the agent’s role in the expanding field of T cell–redirecting therapies approved for the treatment of this patient population.
Dr Lonial on the Outcomes of the IKEMA Trial in Relapsed Multiple Myeloma
October 3rd 2023Sagar Lonial, MD, FACP, discusses the final overall survival analysis of the phase 3 IKEMA trial of isatuximab when combined with carfilzomib and dexamethasone in patients with relapsed multiple myeloma, highlighting the progression-free survival and OS outcomes.
FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma
September 21st 2023Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.
Elranatamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-directed Therapy
Treatment with elranatamab monotherapy produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma who received a prior BCMA-directed therapy, according to a pooled analysis of the MagnetisMM-1, MagnetisMM-2, MagnetisMM-3, and MagnetisMM-9 trials.
Ribociclib/Fulvestrant Combo Generates PFS Improvement in Metastatic Breast Cancer
May 23rd 2023Ribociclib plus switch endocrine therapy induced a statistically significant progression-free survival benefit compared with placebo plus switch endocrine therapy in patients with hormone receptor–positive, HER2-negative, metastatic breast cancer.
Manali Bhave, MD, discusses the effect of emerging therapies on the treatment landscape for patients with HR-positive, HER2-negative or -low breast cancer, highlighted her stance on sequencing decisions for these patients, and expanded on the additional work being done to optimize treatment sequencing from a growing list of options.
Phase 2 Data Support Development of Lasofoxifene in ESR1-mutant, ER+/HER2– Breast Cancer
April 19th 2023Jane Lowe Meisel, MD, discusses previously reported data from the ELAINE-1 and ELAINE-2 trials, their significance within the ESR1-mutant, ER-positive, HER2-negative breast cancer treatment paradigm, and the purpose of the ongoing ELAINE-3 trial.
The American Cancer Society, Winship Partner to Accelerate Cancer Research in Georgia
March 24th 2023The American Cancer Society, in partnership with Winship Cancer Institute of Emory University, announced a new project that aims to significantly accelerate cancer research and improve patient outcomes.
Newly Defined Breast Cancer Targets Expand TNBC Treatment Options
March 23rd 2023Kevin Kalinsky, MD, MS, discusses genetic sequencing in triple-negative breast cancer, the significance of breast cancer tumor board discussions for informing further research and optimizing patient care, and how future directions in breast cancer treatment are building off the current benefits of drugs classes like antibody-drug conjugates.